Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells

被引:24
|
作者
Yamashita, Naoya [1 ]
Saito, Nao [1 ]
Zhao, Shuai [1 ]
Terai, Kensuke [2 ,3 ]
Hiruta, Nobuyuki [2 ,3 ]
Park, Youngjin [4 ,5 ]
Bujo, Hideaki [2 ]
Nemoto, Kiyomitsu [1 ]
Kanno, Yuichiro [5 ]
机构
[1] Toho Univ, Fac Pharmaceut Sci, Dept Mol Toxicol, Miyama 2-2-1, Funabashi, Chiba 2748510, Japan
[2] Toho Univ, Sakura Med Ctr, Dept Clin Lab & Expt Res Med, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[3] Toho Univ, Sakura Med Ctr, Dept Surg Pathol, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[4] Toho Univ, Sakura Med Ctr, Dept Surg, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[5] Tohoku Med & Pharmaceut Univ, Dept Breast & Endocrine Surg, Fukumuro 1-15-1, Sendai, Miyagi 9838536, Japan
基金
日本学术振兴会;
关键词
Breast cancer; AhR; Heregulin; HER2; HER3; MAMMOSPHERE FORMATION; EXPRESSION; REVEALS; TRANSCRIPTION; METASTASIS; ACTIVATION; NETWORK; GROWTH; ERBB3; HER2;
D O I
10.1016/j.yexcr.2018.02.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 overexpression accounts for approximately 15-20% of all breast cancers. We have shown that HER2 overexpression leads to elevated expression of the aryl hydrocarbon receptor (AhR) in breast cancer cells. In this study, firstly, we showed that AhR expression was up-regulated by treatment with the HER3 ligand heregulin (HRG) in HER2-overexpressing breast cancer cell lines. Induction of AhR was mediated by transcriptional activation of the region of AhR promoter corresponding to -190 to -100 bp. In addition, HRG treatment elicited nuclear translocation of AhR. To investigate the role of AhR in HRG-HER2/HER3 signaling in HER2-overexpressing cells, we established AhR knockout (KO) HER2-overexpressing cells to perform wound-healing assays. HRG-induced cell migration was markedly attenuated by AhR KO. HRG-induced cell migration was associated with increased expression of the inflammatory cytokines interleukin (IL)-6 and IL-8 in wild type cells, but not in AhR KO cells. These results elucidate that AhR is an important factor for the malignancy in HER2-overexpressing breast cancers.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [31] Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
    Emde, Anna
    Koestler, Wolfgang J.
    Yarden, Yosef
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 : E49 - E57
  • [32] Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
    Zhang, Dongwei
    Pal, Ashutosh
    Bornmann, William G.
    Yamasaki, Fumiyuki
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    Bartholomeusz, Chandra
    Ueno, Naoto T.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) : 1846 - 1850
  • [33] HER2 down-modulation increases sensitivity to trastuzumab in HER2-overexpressing breast cancer cells
    Valabrega, Giorgio
    Montemurro, Filippo
    Aglietta, Massimo
    Giordano, Silvia
    ANNALS OF ONCOLOGY, 2005, 16 : 30 - 30
  • [34] PIPERINE DOWNREGULATES HER2 EXPRESSION, LEADING TO INHIBITION OF HER2-MEDIATED PROLIFERATION, MIGRATION AND APOPTOSIS POTENTIALS IN HER2-OVEREXPRESSING BREAST CANCER CELLS
    Kim, Hyung Gyun
    Minh Truong Do
    Jeong, Hye Gwang
    DRUG METABOLISM REVIEWS, 2014, 45 : 59 - 59
  • [35] Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
    Park, Yeon Hee
    Lee, Soohyeon
    Cho, Eun Yoon
    Choi, Yoon La
    Lee, Jeong Eon
    Nam, Seok Jin
    Yang, Jung-Hyun
    Ahn, Jin Seok
    Im, Young-Hyuck
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 507 - 516
  • [36] Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
    Yeon Hee Park
    Soohyeon Lee
    Eun Yoon Cho
    Yoon La Choi
    Jeong Eon Lee
    Seok Jin Nam
    Jung-Hyun Yang
    Jin Seok Ahn
    Young-Hyuck Im
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 507 - 516
  • [37] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
  • [38] Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer
    O'Sullivan, Ciara C.
    Swain, Sandra M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 779 - 790
  • [39] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Underutilization of anthracyclines in the management of HER2-overexpressing advanced breast cancer patients
    Montemurro, F.
    Redana, S.
    Valabrega, G.
    Donadio, M.
    Jacomuzzi, M. E.
    Vietti-Ramus, G.
    Clavarezza, M.
    Danese, S.
    Durando, A.
    Venturini, M.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI9 - XI10